Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAR443726 study in moderate-to-severe atopic dermatitis
NL-OMON51621Phase 1Withdrawn
- Sponsor
- Sanofi
- Start
- Nov 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing SAR443726 with Placebo (2 arms). Primary endpoints: Assessment of adverse events and treatment-emergent adverse events, Clinical laboratory evaluations and 2 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
SAR443726
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON51621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51621.